Skip to content
OpenCapital
Get started

Viatris VTRS Lipitor — Net Sales

Other product segments

Brands
$2.33B+10.2%
Generics
$1.18B+4.5%
Norvasc
$210M+21.9%
Lyrica ®
$120.6M+7.1%
EpiPen® Auto-Injectors
$101.1M+4.6%
Creon ®
$97.4M+18.2%
Viagra ®
$95M-3.6%
Zoloft ®
$72.6M+20.6%
Celebrex ®
$67.1M+5.8%
Yupelri ®
$62.5M+7.2%
Effexor ®
$62M+4.6%
Xalabrands
$39.2M+5.7%
Dymista ®
$37.3M-12.9%
Xanax ®
$34.8M+7.7%

Similar metrics at other companies

Mirum Pharmaceuticals, Inc. logo
MIRMProduct sales, net — Product sales, net
$159.88M+43.3%
Mirum Pharmaceuticals, Inc. logo
MIRMBile Acid Medicines — Product sales, net
$46.08M+20.1%
Organon logo
OGNVytorin — Revenue
$21M-8.7%
Incyte logo
INCYNet sales — Total revenues
$1.1B+19.8%
Ardelyx logo
ARDXProduct sales, net — Total revenues
$93.37M+37.7%
Esperion Therapeutics logo
ESPRProduct sales, net — Total Revenues
$43.4M+24.3%

Other financials

Income statement

See full
Revenue$3.5B+8.1%
Gross profit$1.2B-0.3%
Operating income-$79.7M+97.2%
Net income$176.4M+106%
EPS (diluted)$0.15+106%

Balance sheet

See full
Cash & equivalents$1.8B+139%
Total debt$14.6B+1.0%
Total equity$14.7B-6.3%
Total assets$36.8B-4.3%

Cash flow

See full
Operating cash flow$388.3M-27.5%
CapEx$39.9M-6.3%
Free cash flow$348.4M-29.3%

Valuation

See full
Market cap$18.49B+81.7%
Enterprise value$31.3B+29.5%
P/S1.3×+0.5×

Profitability

See full
Gross margin34.4%-2.5pp
Operating margin1%—
Net margin-2%-1.0pp
FCF margin12.3%-1.0pp

Returns & leverage

See full
Return on equity-2%-0.9pp
Debt / equity1×+0.1×
Current ratio1.6×-0.1×

Where this comes from

Reported directly by Viatris in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Viatris’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viatris's lipitor — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viatris's lipitor — net sales?
Viatris (VTRS) reported lipitor — net sales of $462M in Q1 2026.
How has Viatris's lipitor — net sales changed year-over-year?
Viatris's lipitor — net sales increased by 19.1% year-over-year, from $388M to $462M.
What is the long-term trend for Viatris's lipitor — net sales?
Over 4 years (2021 to 2025), Viatris's lipitor — net sales has grown at a -1.8% compound annual growth rate (CAGR), from $1.66B to $1.55B.
What does lipitor — net sales mean?
This metric represents the total revenue generated from the sale of Lipitor, a cholesterol-lowering statin medication, after accounting for returns, allowances, and rebates. As a legacy branded product within the company's portfolio, it serves as a key indicator of the performance of established, off-patent pharmaceutical assets. Monitoring these sales helps investors assess the lifecycle management and cash flow stability of mature, non-generic drug franchises.